CLL/SLL Clinical Trial
Official title:
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study)
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Approximately 440 patients will be enrolled, the patients who meet the eligibility criteria will be randomized in a 1:1 ratio to investigational arm (lisaftoclax in combination with a BTK inhibitor) or the control arm (BTK inhibitor alone). These patients with CLL/SLL have been on BTKi monotherapy and meet all other protocol required eligibility criteria. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05487651 -
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT05590702 -
French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings
|
||
| Withdrawn |
NCT04660045 -
Early Intervention With Acalabrutinib in Patients With High Risk CLL
|
Phase 2 | |
| Recruiting |
NCT04215809 -
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
|
Phase 1 | |
| Recruiting |
NCT05665062 -
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT05975164 -
the Real World Study of Orelabrutinib in the Treatment of CLL/SLL
|
||
| Withdrawn |
NCT05365100 -
A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04775745 -
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
|
Phase 1 | |
| Not yet recruiting |
NCT05918276 -
Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL
|
Phase 2 | |
| Recruiting |
NCT05920668 -
Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma
|
||
| Recruiting |
NCT05269940 -
A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05491044 -
A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib
|
Phase 2 | |
| Withdrawn |
NCT05176691 -
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
|
Phase 1 | |
| Terminated |
NCT04149821 -
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
|
Phase 2 | |
| Recruiting |
NCT04523428 -
REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
|
Phase 2 | |
| Withdrawn |
NCT04694560 -
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
|
||
| Recruiting |
NCT06319456 -
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
|
Phase 3 | |
| Active, not recruiting |
NCT03493217 -
A Study to Evaluate ICP-022 in Patients With CLL/ SLL
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05791409 -
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
|
Phase 1/Phase 2 |